Le Lézard
Classified in: Health, Science and technology
Subject: CHI

Ambrosia launches revolutionary "Direct-to-Apple Watch" NightRider BluCon for Continuous Glucose Monitoring


SAN FRANCISCO, July 19, 2019 /PRNewswire/ -- Ambrosia Systems, a fast growing medical  technology company, today announced the launch of the next version of NightRider BluCon. The new NightRider BluCon works with Apple watch to display glucose readings from the FreeStyle Libre and Libre Pro sensors on Apple watch without the phone. This will help parents of the millions of Type 1 diabetic children monitor their children's glucose levels when the child is away. Currently, parents don't have a way to know the current glucose levels of their Type 1 diabetic child if he or she is not carrying their phone, which most schools don't allow. Also, it is difficult for young children to carry their phone all the time.

Glucose Reading from FreeStyle Libre Sensor direct-to-Apple Watch

After the initial setup of Ambrosia's NightRider and LinkBluCon app on the iPhone, the user can change the mode to Apple Watch on LinkBluCon's settings screen, this will switch the NightRider connection from the iPhone to Apple Watch and will start displaying glucose readings on Apple Watch without the phone. If Apple Watch has a cellular connection, parents can install Ambrosia's FollowBluCon app on their phone and, after setup, will be able to see glucose readings updates of their child every five minutes.

Disclaimer:

Ambrosia apps are not FDA approved and should not be used to make medical decisions.
FreeStyle Libre is a trademark of Abbott Diabetes Care Inc. Ambrosia Systems Inc. does not have any kind of relationship with Abbott Diabetic Care or Abbott Laboratories.

About Ambrosia Systems

Ambrosia Systems is a fast growing medical technology company focused on building easy to use and affordable technology solutions for patients, providers, payers and caregivers. The NightRider BluCon is currently in use in more than 100 countries with FreeStyle Libre, FreeStyle Libre 2 and FreeStyle Libre Pro sensors. To learn more, visit www.ambrosiasys.com

Media Contacts: Mia Flaherty, Ambrosia Systems Inc. [email protected], +1-415-293-8242

SOURCE Ambrosia Systems


These press releases may also interest you

at 22:15
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

at 21:59
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 21:27
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

at 21:19
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

at 21:05
Valcare Medical, Inc., a leading innovator in transcatheter-based mitral...

at 21:02
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...



News published on and distributed by: